Immunovant Inc Earnings

Immunovant Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2025. On a quarterly growth basis, Immunovant Inc has generated -100% fall in its revenue since last 3-months.

Immunovant Inc’s net profit fell -38.4% since last year same period to $-120.61Mn in the Q2 2025. On a quarterly growth basis, Immunovant Inc has generated -13.31% fall in its net profits since last 3-months.

Immunovant Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2025. On a quarterly growth basis, Immunovant Inc has generated -Inf% fall in its net profit margins since last 3-months.

Immunovant Inc’s earning per share (EPS) estimates for the current quarter stand at -0.71 - a -1.86% fall from last quarter’s estimates.

Immunovant Inc’s earning per share (EPS) estimates for the current year stand at -0.71.

Immunovant Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Immunovant Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.